| Product Code: ETC7741132 | Publication Date: Sep 2024 | Updated Date: Oct 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Vasudha | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
In 2024, Japan continued to see significant import shipments of large volume parenteral products, with top exporting countries being Germany, Switzerland, USA, Italy, and Metropolitan France. Despite a low concentration level indicated by the HHI, the market experienced a negative CAGR of -5.32% from 2020 to 2024. However, there was a slight improvement in the growth rate from 2023 to 2024, with a decline of -3.46%. This data suggests a challenging market environment, possibly influenced by various factors affecting the import dynamics of large volume parenteral products in Japan.

The Japan Large Volume Parenteral (LVP) market is characterized by a growing demand for intravenous solutions administered in volumes exceeding 100 ml. Factors driving market growth include an increasing geriatric population, rising prevalence of chronic diseases, and advanced healthcare infrastructure. The market is dominated by key players such as Otsuka Pharmaceutical, Terumo Corporation, and Nipro Corporation, who offer a wide range of LVP products to cater to the diverse healthcare needs in Japan. Regulatory initiatives focusing on quality assurance and safety measures further contribute to the market`s stability. Strong emphasis on product innovation, quality control, and technological advancements are expected to sustain market growth in the forecast period, with a particular focus on enhancing patient outcomes and improving overall healthcare delivery in Japan.
The Japan Large Volume Parenteral (LVP) market is experiencing a growing demand due to the increasing prevalence of chronic diseases and the aging population. One of the key trends in the market is the shift towards ready-to-use LVPs, which offer convenience and reduce the risk of medication errors. Another trend is the adoption of advanced technologies such as robotics and automation in LVP manufacturing to improve efficiency and quality control. Opportunities in the market include the expansion of product offerings to cater to the diverse healthcare needs of the population, as well as partnerships and collaborations with hospitals and healthcare providers to enhance distribution channels. Overall, the Japan LVP market is poised for growth, driven by the need for safe and effective parenteral medications in the healthcare sector.
In the Japan Large Volume Parenteral (LVP) market, some challenges include strict regulatory requirements for manufacturing and distribution, increasing competition from local and international players, and the need for continuous innovation to meet changing healthcare demands. The stringent regulations often lead to lengthy approval processes and higher production costs, impacting the overall market growth. Additionally, the presence of well-established domestic manufacturers alongside the entry of new players intensifies competition, leading to price pressures and the need for differentiation through quality and service offerings. To navigate these challenges, companies in the Japan LVP market must invest in research and development, maintain high quality standards, and forge strategic partnerships to enhance their market position and sustain growth in the competitive landscape.
The Japan Large Volume Parenteral market is driven by several key factors. One of the primary drivers is the increasing prevalence of chronic diseases and the growing aging population in Japan, leading to a rise in the demand for intravenous therapy. Additionally, advancements in healthcare infrastructure and technology have improved the accessibility and safety of large volume parenteral products, further fueling market growth. The government`s initiatives to promote the use of sterile and high-quality parenteral products in healthcare facilities also contribute to market expansion. Moreover, the rising number of surgeries and medical procedures requiring intravenous administration of fluids and medications drive the demand for large volume parenteral products in Japan. Overall, these factors are driving the growth of the Japan Large Volume Parenteral market.
In Japan, the Large Volume Parenteral (LVP) market is regulated by the Pharmaceuticals and Medical Devices Agency (PMDA) under the Ministry of Health, Labour and Welfare (MHLW). The government has implemented stringent regulations to ensure the quality, safety, and efficacy of LVP products, with a focus on Good Manufacturing Practice (GMP) standards. Manufacturers are required to obtain marketing approval from the PMDA before selling LVP products in the Japanese market. Additionally, pricing and reimbursement policies set by the government impact the market dynamics, with a focus on cost-effectiveness and accessibility of essential healthcare products. Continuous monitoring and assessment of LVP products are conducted to maintain high standards and protect public health.
The Japan Large Volume Parenteral market is expected to experience steady growth in the coming years, driven by factors such as the increasing prevalence of chronic diseases, growing aging population, and advancements in healthcare infrastructure. The market is likely to benefit from the rising demand for intravenous therapies and injectable medications, as well as the emphasis on patient safety and convenience. Additionally, the expansion of the pharmaceutical industry in Japan and the rising adoption of parenteral nutrition solutions are expected to further propel market growth. However, regulatory challenges and pricing pressures may pose some hurdles for market players. Overall, with the increasing focus on healthcare quality and patient outcomes, the Japan Large Volume Parenteral market is forecasted to witness positive growth prospects in the foreseeable future.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Japan Large Volume Parenteral Market Overview |
3.1 Japan Country Macro Economic Indicators |
3.2 Japan Large Volume Parenteral Market Revenues & Volume, 2021 & 2031F |
3.3 Japan Large Volume Parenteral Market - Industry Life Cycle |
3.4 Japan Large Volume Parenteral Market - Porter's Five Forces |
3.5 Japan Large Volume Parenteral Market Revenues & Volume Share, By Type, 2021 & 2031F |
3.6 Japan Large Volume Parenteral Market Revenues & Volume Share, By Volume, 2021 & 2031F |
3.7 Japan Large Volume Parenteral Market Revenues & Volume Share, By Application, 2021 & 2031F |
3.8 Japan Large Volume Parenteral Market Revenues & Volume Share, By End-Users, 2021 & 2031F |
3.9 Japan Large Volume Parenteral Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Japan Large Volume Parenteral Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing geriatric population in Japan leading to higher demand for healthcare services and treatments. |
4.2.2 Rise in chronic diseases and medical conditions requiring parenteral administration of drugs. |
4.2.3 Technological advancements in parenteral drug delivery systems improving efficiency and safety. |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for manufacturing and distribution of large volume parenteral products. |
4.3.2 Concerns regarding potential contamination and infection risks associated with parenteral administration. |
4.3.3 Competition from alternative drug delivery methods such as oral or transdermal routes. |
5 Japan Large Volume Parenteral Market Trends |
6 Japan Large Volume Parenteral Market, By Types |
6.1 Japan Large Volume Parenteral Market, By Type |
6.1.1 Overview and Analysis |
6.1.2 Japan Large Volume Parenteral Market Revenues & Volume, By Type, 2021- 2031F |
6.1.3 Japan Large Volume Parenteral Market Revenues & Volume, By Soft Bag LVP, 2021- 2031F |
6.1.4 Japan Large Volume Parenteral Market Revenues & Volume, By Plastic Bottle LVP, 2021- 2031F |
6.1.5 Japan Large Volume Parenteral Market Revenues & Volume, By Glass Bottle LVP, 2021- 2031F |
6.2 Japan Large Volume Parenteral Market, By Volume |
6.2.1 Overview and Analysis |
6.2.2 Japan Large Volume Parenteral Market Revenues & Volume, By 100 ml-250 ml, 2021- 2031F |
6.2.3 Japan Large Volume Parenteral Market Revenues & Volume, By 250 ml-500 ml, 2021- 2031F |
6.2.4 Japan Large Volume Parenteral Market Revenues & Volume, By 500 ml-1000 ml, 2021- 2031F |
6.2.5 Japan Large Volume Parenteral Market Revenues & Volume, By 1000 ml-2000 ml, 2021- 2031F |
6.2.6 Japan Large Volume Parenteral Market Revenues & Volume, By 2000 ml and more, 2021- 2031F |
6.3 Japan Large Volume Parenteral Market, By Application |
6.3.1 Overview and Analysis |
6.3.2 Japan Large Volume Parenteral Market Revenues & Volume, By Therapeutic Injections, 2021- 2031F |
6.3.3 Japan Large Volume Parenteral Market Revenues & Volume, By Fluid Balance Injections, 2021- 2031F |
6.3.4 Japan Large Volume Parenteral Market Revenues & Volume, By Nutritious Injections, 2021- 2031F |
6.4 Japan Large Volume Parenteral Market, By End-Users |
6.4.1 Overview and Analysis |
6.4.2 Japan Large Volume Parenteral Market Revenues & Volume, By Clinic, 2021- 2031F |
6.4.3 Japan Large Volume Parenteral Market Revenues & Volume, By Hospital, 2021- 2031F |
6.4.4 Japan Large Volume Parenteral Market Revenues & Volume, By Others, 2021- 2031F |
6.5 Japan Large Volume Parenteral Market, By Distribution Channel |
6.5.1 Overview and Analysis |
6.5.2 Japan Large Volume Parenteral Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.5.3 Japan Large Volume Parenteral Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
6.5.4 Japan Large Volume Parenteral Market Revenues & Volume, By Online Pharmacy, 2021- 2031F |
7 Japan Large Volume Parenteral Market Import-Export Trade Statistics |
7.1 Japan Large Volume Parenteral Market Export to Major Countries |
7.2 Japan Large Volume Parenteral Market Imports from Major Countries |
8 Japan Large Volume Parenteral Market Key Performance Indicators |
8.1 Rate of adoption of advanced parenteral drug delivery systems in healthcare facilities. |
8.2 Number of approvals for new large volume parenteral products by regulatory authorities. |
8.3 Patient satisfaction scores related to the convenience and effectiveness of parenteral treatments. |
8.4 Trends in healthcare expenditure on parenteral medications in Japan. |
8.5 Rate of hospital-acquired infections related to parenteral administration. |
9 Japan Large Volume Parenteral Market - Opportunity Assessment |
9.1 Japan Large Volume Parenteral Market Opportunity Assessment, By Type, 2021 & 2031F |
9.2 Japan Large Volume Parenteral Market Opportunity Assessment, By Volume, 2021 & 2031F |
9.3 Japan Large Volume Parenteral Market Opportunity Assessment, By Application, 2021 & 2031F |
9.4 Japan Large Volume Parenteral Market Opportunity Assessment, By End-Users, 2021 & 2031F |
9.5 Japan Large Volume Parenteral Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Japan Large Volume Parenteral Market - Competitive Landscape |
10.1 Japan Large Volume Parenteral Market Revenue Share, By Companies, 2024 |
10.2 Japan Large Volume Parenteral Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |